Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Isoniazid
Drug ID BADD_D01204
Description Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Indications and Usage For the treatment of all forms of tuberculosis in which organisms are susceptible.
Marketing Status approved; investigational
ATC Code J04AC01
DrugBank ID DB00951
KEGG ID D00346
MeSH ID D007538
PubChem ID 3767
TTD Drug ID D09XQF
NDC Product Code 60687-553; 0555-0071; 71610-395; 83112-071; 50090-0410; 63187-978; 0555-0066; 68788-9405; 71610-108; 12785-0003; 50090-0370; 70518-0096; 70518-2576; 43063-463; 62135-550; 0781-3056; 12785-0002; 66639-914; 51079-083; 43367-0100; 71052-611; 46287-009; 71335-0275; 53002-2920
UNII V83O1VOZ8L
Synonyms Isoniazid | Isonicotinic Acid Hydrazide | Hydrazide, Isonicotinic Acid | Phthivazide | Phthivazid | Isonicotinic Acid Vanillylidenehydrazide | Acid Vanillylidenehydrazide, Isonicotinic | Vanillylidenehydrazide, Isonicotinic Acid | Ftivazide | Tubazide | Isonex
Chemical Information
Molecular Formula C6H7N3O
CAS Registry Number 54-85-3
SMILES C1=CN=CC=C1C(=O)NN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemoglobin decreased13.01.05.003--Not Available
Haemoglobinuria01.06.04.005; 20.02.01.017--
Haemolysis01.06.04.002--
Haemolytic anaemia01.06.03.002--Not Available
Haemoptysis24.07.01.006; 22.02.03.004; 02.11.04.0090.002780%Not Available
Haemorrhage subcutaneous24.07.06.010; 23.06.07.0020.002780%Not Available
Hallucinations, mixed19.10.04.0080.002780%Not Available
Headache17.14.01.001--
Hepatic atrophy09.01.08.0040.002780%Not Available
Hepatic cirrhosis09.01.04.0010.008895%Not Available
Hepatic encephalopathy09.01.03.006; 17.13.01.0030.020014%Not Available
Hepatic failure09.01.03.0020.019458%
Hepatic fibrosis24.08.06.002; 09.01.04.0020.006115%Not Available
Hepatic function abnormal09.01.02.0010.036693%Not Available
Hepatic necrosis09.01.07.0020.013065%
Hepatic steatosis14.08.04.005; 09.01.07.0030.006115%Not Available
Hepatitis09.01.07.0040.023628%Not Available
Hepatitis acute09.01.07.0050.011675%Not Available
Hepatitis cholestatic09.01.01.0020.014455%Not Available
Hepatitis fulminant11.07.01.003; 09.01.07.0070.006949%Not Available
Hepatitis toxic12.03.01.016; 09.01.07.0170.027798%Not Available
Hepatocellular injury09.01.07.0080.013899%Not Available
Hepatomegaly09.01.05.0010.016957%Not Available
Hepatosplenomegaly01.09.03.001; 09.01.05.0020.002780%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.124533%Not Available
Hydronephrosis20.01.05.001--Not Available
Hyperammonaemia14.10.01.001; 09.01.02.0020.002780%Not Available
Hyperbilirubinaemia14.11.01.010; 09.01.01.003; 01.06.04.0030.005560%Not Available
Hypercalcaemia14.04.01.003; 05.04.01.0020.002780%
Hyperglycaemia14.06.02.002; 05.06.02.0020.004170%
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene